This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
by Arpita Dutt
Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
by Arpita Dutt
Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.
Mylan Receives Tentative Approval from FDA for HIV Therapy
by Zacks Equity Research
Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).
Biotech Bull Making a Comeback
by Kevin Cook
A triple-bottom at $240 was bolstered by the headline capitulation of an infamous Valeant investor
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
by Arpita Dutt
Gilead's (GILD) valuation looks compelling but is the company really poised for
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
by Arpita Dutt
The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.
Forget Gilead, Buy These Small-Cap Biotech Stocks Instead
by Zacks Equity Research
At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.
Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
by Zacks Equity Research
We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.
Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal
by Arpita Dutt
Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.
Is This the Right Time to Invest in Biotech Stocks?
by Arpita Dutt
The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
Biotech ETF (BBH) Hits New 52-Week High
by Sweta Killa
This biotech ETF hit a new 52-week high. Are more gains in store for this ETF?
Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) reported wider than expected loss in the fourth quarter of 2016.
Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
by Arpita Dutt
Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.
Pricing to Remain Pharma Headline Risk in 2017
by Arpita Dutt
Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.
United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
by Zacks Equity Research
United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
by Arpita Dutt
While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.
Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead
Five Major Myths about Options Trading
by David Bartosiak
These are the five biggest myths about options trading
Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)
by Zacks Equity Research
Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
by Arpita Dutt
Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.
Gilead (GILD) Announces Data on Combination Therapy for HIV
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
by Zacks Equity Research
The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.